 |
Journal articles
Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response
Abstract : Interleukin-7 (IL-7) is a critical cytokine in B- and T-lymphocyte development and maturation. Recent evidence suggests that IL-7 is a preferential homeostatic and survival factor for RORγt+ innate T cells such as natural killer T (NKT) cells, γδT cells, and mucosal-associated invariant T (MAIT) cells in the periphery. Given the important contribution of these populations in antibacterial immunity at barrier sites, we questioned whether IL-7 could be instrumental in boosting the local host immune response against respiratory bacterial infection. By using a cytokine-monoclonal antibody approach, we illustrated a role for topical IL-7 delivery in increasing the pool of RORγt+ IL-17A-producing innate T cells. Prophylactic IL-7 treatment prior to Streptococcus pneumoniae infection led to better bacterial containment, a process associated with increased neutrophilia and that depended on γδT cells and IL-17A. Last, combined delivery of IL-7 and α-galactosylceramide (α-GalCer), a potent agonist for invariant NKT (iNKT) cells, conferred an almost total protection in terms of survival, an effect associated with enhanced IL-17 production by innate T cells and neutrophilia. Collectively, we provide a proof of concept that IL-7 enables fine-tuning of innate T- cell functions. This might pave the way for considering IL-7 as an innovative biotherapeutic against bacterial infection.
https://www.hal.inserm.fr/inserm-03385211
Contributor : François Trottein Connect in order to contact the contributor
Submitted on : Tuesday, October 19, 2021 - 1:56:28 PM
Last modification on : Tuesday, January 25, 2022 - 6:40:03 PM
Long-term archiving on: : Thursday, January 20, 2022 - 7:04:03 PM
Contributor : François Trottein Connect in order to contact the contributor
Submitted on : Tuesday, October 19, 2021 - 1:56:28 PM
Last modification on : Tuesday, January 25, 2022 - 6:40:03 PM
Long-term archiving on: : Thursday, January 20, 2022 - 7:04:03 PM